Investment analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of PULM stock opened at $2.05 on Friday. The stock has a fifty day moving average price of $2.07 and a 200 day moving average price of $2.03. The stock has a market cap of $7.49 million, a PE ratio of -0.78 and a beta of 0.99. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The firm had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Transportation Stocks Investing
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What is a Dividend King?
- MarketBeat Week in Review – 11/4 – 11/8
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
